KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to -$34.4 million.

  • Twist Bioscience's Net Cash Flow fell 58623.51% to -$34.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$73.3 million, marking a year-over-year decrease of 6279.16%. This contributed to the annual value of -$43.8 million for FY2025, which is 2725.01% up from last year.
  • As of Q4 2025, Twist Bioscience's Net Cash Flow stood at -$34.4 million, which was down 58623.51% from -$18.6 million recorded in Q3 2025.
  • In the past 5 years, Twist Bioscience's Net Cash Flow ranged from a high of $216.0 million in Q1 2022 and a low of -$274.2 million during Q4 2021
  • For the 5-year period, Twist Bioscience's Net Cash Flow averaged around -$10.0 million, with its median value being -$10.3 million (2021).
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 32775.49% in 2022, then plummeted by 132451.65% in 2024.
  • Quarter analysis of 5 years shows Twist Bioscience's Net Cash Flow stood at -$274.2 million in 2021, then skyrocketed by 77.6% to -$61.4 million in 2022, then surged by 66.99% to -$20.3 million in 2023, then skyrocketed by 75.25% to -$5.0 million in 2024, then plummeted by 586.24% to -$34.4 million in 2025.
  • Its last three reported values are -$34.4 million in Q4 2025, -$18.6 million for Q3 2025, and -$9.0 million during Q2 2025.